Chiefs cut Amerson, veterans as they reach 53-man limit
Reported by FOX Sports 22 hours ago.
Chiefs cut Amerson, veterans as they reach 53-man limit
↧
↧
Blumenthal co-sponsors bill on 1966 Spain H-bomb accident
HARTFORD, Conn. (AP) — U.S. Sen. Richard Blumenthal is co-sponsoring a bill that would ensure health care and other benefits for military veterans who became ill from radiation exposure after responding to a 1966 accident involving...
Reported by New Zealand Herald 21 hours ago.
↧
Warriors veterans call for cool heads in NRL finals
The Warriors, who have recently beaten all the teams they may meet in the finals, like their chances in the NRL playoffs.
Reported by Brisbane Times 20 hours ago.
↧
Newest Dodgers get right into action
World Series-winning veterans David Freese and Ryan Madson wasted no time before joining the Dodgers after their Friday acquisitions, Freese penciled in to start at first base and Madson ready for bullpen duty in Saturday night's game against the D-backs.
Reported by MLB.com 19 hours ago.
↧
Liberal treasury promotion a 'joke': Labor
An elevation to assistant treasurer for former minister for veterans affairs Stuart Robert has been called a "joke" by Labor's financial services spokeswoman.
Reported by SBS 18 hours ago.
↧
↧
Fifteen Ways The Democrats Can Lose The November Elections – OpEd
*1. Focus* on Donald Trump’s personal scandals, the Russian interference, and Trump’s outrageous and hugely distracting daily tweets.
*2. Overlook* what Trump’s henchmen are specifically doing to cause more deaths, injuries, and disease. Ignore this administration’s efforts to scuttle health and safety standards; stop law enforcement against corporate outlaws who pollute the environment, marketplace, and workplace; take federal cops off the Wall Street crime beat that is eating into your savings, while speculating with your pensions and mutual funds. Avoid all the above, while you’re dialing for dollars for your campaign coffers.
*3.* *Giving lip service* to raising the federal minimum wage. Do not mount a tough, authentic campaign with details and timetables to help the 30 million Americans still making less than workers made in 1968, adjusted for inflation.
*4. Avoid talking* about the need to crack down on corporate crooks who are bleeding Americans dry—to the tune of one trillion dollars a year.
*5. Refuse to put forward* a Canadian style healthcare for all system, with free choices of doctors and hospitals. Single payer would result in life-saving outcomes and come in at half the per capita cost of the current price gouging, wasteful, claim-denying monstrosity ruled by big insurance companies, big drug companies and big hospital chains.
*6. Do not talk* specifics about public corruption. *Do not put* forward a detailed plan to take on corruption with adequate enforcement budgets and penalties that fit the crimes.
*7. Do not talk* *about* public funding of campaigns, clean elections, universal voting (with write-ins and none-of-the-above options), ending voter suppression, and returning to paper ballots that can never be hacked. Keep spending huge amounts of your time at fat-cat fundraising parties or calling possible donors on the phone.
*8. Fail to speak* forcefully for more workers rights and strong labor unions, more consumer protections, and more access to the courts for wrongfully injured or defrauded Americans. Fail to focus more on climate disruption, the bloated military budget that is draining our public infrastructure and depriving Americans of good jobs. Keep censoring yourself by treating these causes like taboo subjects.
*9. Never mention education reform* meaning students learning civic skills from books and experiential learning in their communities. Prohibit the seeds of democracy from being planted. Do not push for cracking down on fraudulent for-profit universities and forgiving student debt, ending massive corporate tax loopholes and starting tuition-free higher public education.
*10. Be sure to ignore important local issues of concern* that affect already engaged conservative and liberal voters. The powers-that-be at all levels have few votes compared to the vast number of eligible voters. Be sure that you spend most of your campaign money on redundant television ads rather than on neighborhood by neighborhood get-out-the-vote drives.
*11. Make sure you rehire those conflicted*, avaricious political consultants who have already been overly paid to lose the last four Congressional elections to the worse, most corrupt, war mongering, Wall Street toady, anti-worker, anti-consumer, and anti-environment Republican Party in history. Give these consultants another chance to deep-six your close races.
*12. Avoid connecting with* the emerging left/right alliance for criminal justice reform of mass incarceration, brutish prison conditions, runaway prosecutors, and the war on drugs.
*13. Do not address the horrific costs of Empire*. Ignore the futile wars without end, the blowbacks and destruction of innocent peoples and their communities in more and more countries, the violations of our Constitution. Stand by as the federal government violates federal laws and international treaties. Especially ignore what most of our returning veterans want to tell us about these boomeranging disasters spawned by both parties.
*14. Don’t get near* the fundamental issue of shifting power from the few to the many, of building democratic institutions, of providing inexpensive facilities so people can more easily band together to protect themselves. (If you don’t know what all this involves, that is because you’ve frozen out the civil society from your sterile campaigns, which historically has been the builder of a more just democracy).
*15. Stifle the progressive, young insurgents in the Democratic Party*, as you did with Bernie Sanders’ primary campaign in 2016. Again entrench the old Guard of loser Democratic apparatchiks.
*If you do all the above*, the Republicans will continue to enjoy their control of the federal branches of our captured government and many state legislatures. It is time for Democrats to stop singing from the corporate state’s songbook, and really stand “with liberty and justice for all.” Reported by Eurasia Review 18 hours ago.
*2. Overlook* what Trump’s henchmen are specifically doing to cause more deaths, injuries, and disease. Ignore this administration’s efforts to scuttle health and safety standards; stop law enforcement against corporate outlaws who pollute the environment, marketplace, and workplace; take federal cops off the Wall Street crime beat that is eating into your savings, while speculating with your pensions and mutual funds. Avoid all the above, while you’re dialing for dollars for your campaign coffers.
*3.* *Giving lip service* to raising the federal minimum wage. Do not mount a tough, authentic campaign with details and timetables to help the 30 million Americans still making less than workers made in 1968, adjusted for inflation.
*4. Avoid talking* about the need to crack down on corporate crooks who are bleeding Americans dry—to the tune of one trillion dollars a year.
*5. Refuse to put forward* a Canadian style healthcare for all system, with free choices of doctors and hospitals. Single payer would result in life-saving outcomes and come in at half the per capita cost of the current price gouging, wasteful, claim-denying monstrosity ruled by big insurance companies, big drug companies and big hospital chains.
*6. Do not talk* specifics about public corruption. *Do not put* forward a detailed plan to take on corruption with adequate enforcement budgets and penalties that fit the crimes.
*7. Do not talk* *about* public funding of campaigns, clean elections, universal voting (with write-ins and none-of-the-above options), ending voter suppression, and returning to paper ballots that can never be hacked. Keep spending huge amounts of your time at fat-cat fundraising parties or calling possible donors on the phone.
*8. Fail to speak* forcefully for more workers rights and strong labor unions, more consumer protections, and more access to the courts for wrongfully injured or defrauded Americans. Fail to focus more on climate disruption, the bloated military budget that is draining our public infrastructure and depriving Americans of good jobs. Keep censoring yourself by treating these causes like taboo subjects.
*9. Never mention education reform* meaning students learning civic skills from books and experiential learning in their communities. Prohibit the seeds of democracy from being planted. Do not push for cracking down on fraudulent for-profit universities and forgiving student debt, ending massive corporate tax loopholes and starting tuition-free higher public education.
*10. Be sure to ignore important local issues of concern* that affect already engaged conservative and liberal voters. The powers-that-be at all levels have few votes compared to the vast number of eligible voters. Be sure that you spend most of your campaign money on redundant television ads rather than on neighborhood by neighborhood get-out-the-vote drives.
*11. Make sure you rehire those conflicted*, avaricious political consultants who have already been overly paid to lose the last four Congressional elections to the worse, most corrupt, war mongering, Wall Street toady, anti-worker, anti-consumer, and anti-environment Republican Party in history. Give these consultants another chance to deep-six your close races.
*12. Avoid connecting with* the emerging left/right alliance for criminal justice reform of mass incarceration, brutish prison conditions, runaway prosecutors, and the war on drugs.
*13. Do not address the horrific costs of Empire*. Ignore the futile wars without end, the blowbacks and destruction of innocent peoples and their communities in more and more countries, the violations of our Constitution. Stand by as the federal government violates federal laws and international treaties. Especially ignore what most of our returning veterans want to tell us about these boomeranging disasters spawned by both parties.
*14. Don’t get near* the fundamental issue of shifting power from the few to the many, of building democratic institutions, of providing inexpensive facilities so people can more easily band together to protect themselves. (If you don’t know what all this involves, that is because you’ve frozen out the civil society from your sterile campaigns, which historically has been the builder of a more just democracy).
*15. Stifle the progressive, young insurgents in the Democratic Party*, as you did with Bernie Sanders’ primary campaign in 2016. Again entrench the old Guard of loser Democratic apparatchiks.
*If you do all the above*, the Republicans will continue to enjoy their control of the federal branches of our captured government and many state legislatures. It is time for Democrats to stop singing from the corporate state’s songbook, and really stand “with liberty and justice for all.” Reported by Eurasia Review 18 hours ago.
↧
'Discourse about phony controversies and manufactured outrage': When Obama took dig at Trump while remembering McCain
John McCain's daughter *opened his memorial service by posing her father's legacy* as a direct challenge to President Donald Trump, setting a tone that echoed the senator's own fighting spirit as former Presidents Barack Obama and George W Bush eulogised him Saturday at the Washington National Cathedral.
Bush and Obama, both challenged by McCain in their bids for the White House, drew on the senator's legacy at home and abroad to talk of the nation's values in remarks that at times seemed a clear rebuke of Trump and his brand of politics. Obama spoke of the long talks he and McCain would have privately in the Oval Office and the senator's understanding that America's security and influence came not from "our ability to bend others to our will" but universal values of rule of law and human rights.
"So much of our politics, our public life, our public discourse can seem small and mean and petty, tracking in bombast and insult and phony controversies and manufactured outrage," Obama said in another not-so-veiled nod to Trump. "It's a politics that pretends to be brave and tough but in fact is born in fear. John called on us to be bigger than that. He called on us to be better than that." Bush said one of the great gifts in his life was becoming friends with his former White House rival. He said they would in later years recall their political battles like former football players remembering the big game.
But mostly Bush recalled a champion for the "forgotten people" at home and abroad whose legacy will serve as a reminder, even in times of doubt, of the power of America as more than a physical place but a "carrier of human aspirations.""John's voice will always come as a whisper over our shoulder we are better than this, America is better than this," Bush said. Bush, a Republican, and Obama, a Democrat, spoke during the service at McCain's request. Trump was not on hand for the ceremony, after McCain's family made clear he was not invited.
But Meghan McCain made sure Trump was part of the memorial in another way, leveling pointed criticism at the president in her eulogy. "We gather here to mourn the passing of American greatness the real thing, not cheap rhetoric from men who will never come near the sacrifice he gave so willingly, nor the opportunistic appropriation of those who lived lives of comfort and privilege while he suffered and served," she said, her voice first choking back tears then raising to anger. Later, she said to applause, "The America of John McCain has no need to be made great again because America was always great." In another clear swipe at Trump, she said some resented her father for being "a great fire who burned bright" and what he revealed about their own characters. Those critics, she said, still have an opportunity to emulate her father's legacy.
Those gathered Saturday morning to eulogize the six-term senator included three former presidents, scores of members of Congress, current and former world leaders and family and friends. Among those in the front row were Barack and Michelle Obama, George and Laura Bush, Bill and Hillary Clinton, as well as Dick Cheney and Al Gore. McCain's motorcade arrived from the Capitol, where he laid in state overnight, and the procession made a stop at the Vietnam Veterans Memorial, where McCain's wife, Cindy, placed a wreath. His flag-draped casket was escorted by military body bearers up the cathedral steps under gray skies.
It was the last public event in Washington, where McCain lived and worked over four decades, and part of McCain's five-day, cross-country funeral procession. He died on August 25 at age 81. "His death seems to have reminded the American people that these values are what makes us a great nation, not the tribal partisanship and personal attack politics that have recently characterized our life, " said former Sen. Joe Lieberman of Connecticut, a longtime friend and fellow global traveler who McCain once considered as his vice presidential running mate. "This week's celebration of the life and values and patriotism of this hero, I think have taken our country above all that," he said.
"In a way, it's the last great gift that John McCain gave America." Trump, meanwhile, left the White House in the presidential motorcade shortly after 10:30 a.m., as the service was underway, headed to his Virginia golf course. Two of his top aides, White House chief of staff John Kelly and Defense Secretary James Mattis, flanked Cindy McCain as she placed the wreath at the memorial and joine the service. Trump's daughter Ivanka Trump and son-in-law Jared Kushner are attended.
McCain was a decorated veteran who was held for more than five years as a prisoner of war in Vietnam. He refused early release. Trump obtained deferments for his college education and a foot ailment.
McCain had long urged the Senate and the polarized nation to recognize the humanity even in bitter political opponents. McCain's request for speeches by the former presidents, to some, represents that ideal.
Article Type:
Report
Sections:
World
Agencies:
PTI
Tags:
John McCain
Cindy McCain
Meghan McCain
Donald Trump
Ivanka Trump
Barack Obama
Michelle Obama
Washington
James Mattis
Joe Lieberman
Hillary Clinton
Connecticut
White House
Sun, 2 Sep 2018-06:31pm
Date updated:
Sunday, 2 September 2018 - 6:31pm
Article Images:
Reuters
Short URL:
dnai.in/fDeM
Embargo:
Syndicate:
Hide lead image:
Page views:
1
Short Title:
When Obama took dig at Trump while remembering McCain
From Print Edition:
Highlights: Reported by DNA 6 hours ago.
Bush and Obama, both challenged by McCain in their bids for the White House, drew on the senator's legacy at home and abroad to talk of the nation's values in remarks that at times seemed a clear rebuke of Trump and his brand of politics. Obama spoke of the long talks he and McCain would have privately in the Oval Office and the senator's understanding that America's security and influence came not from "our ability to bend others to our will" but universal values of rule of law and human rights.
"So much of our politics, our public life, our public discourse can seem small and mean and petty, tracking in bombast and insult and phony controversies and manufactured outrage," Obama said in another not-so-veiled nod to Trump. "It's a politics that pretends to be brave and tough but in fact is born in fear. John called on us to be bigger than that. He called on us to be better than that." Bush said one of the great gifts in his life was becoming friends with his former White House rival. He said they would in later years recall their political battles like former football players remembering the big game.
But mostly Bush recalled a champion for the "forgotten people" at home and abroad whose legacy will serve as a reminder, even in times of doubt, of the power of America as more than a physical place but a "carrier of human aspirations.""John's voice will always come as a whisper over our shoulder we are better than this, America is better than this," Bush said. Bush, a Republican, and Obama, a Democrat, spoke during the service at McCain's request. Trump was not on hand for the ceremony, after McCain's family made clear he was not invited.
But Meghan McCain made sure Trump was part of the memorial in another way, leveling pointed criticism at the president in her eulogy. "We gather here to mourn the passing of American greatness the real thing, not cheap rhetoric from men who will never come near the sacrifice he gave so willingly, nor the opportunistic appropriation of those who lived lives of comfort and privilege while he suffered and served," she said, her voice first choking back tears then raising to anger. Later, she said to applause, "The America of John McCain has no need to be made great again because America was always great." In another clear swipe at Trump, she said some resented her father for being "a great fire who burned bright" and what he revealed about their own characters. Those critics, she said, still have an opportunity to emulate her father's legacy.
Those gathered Saturday morning to eulogize the six-term senator included three former presidents, scores of members of Congress, current and former world leaders and family and friends. Among those in the front row were Barack and Michelle Obama, George and Laura Bush, Bill and Hillary Clinton, as well as Dick Cheney and Al Gore. McCain's motorcade arrived from the Capitol, where he laid in state overnight, and the procession made a stop at the Vietnam Veterans Memorial, where McCain's wife, Cindy, placed a wreath. His flag-draped casket was escorted by military body bearers up the cathedral steps under gray skies.
It was the last public event in Washington, where McCain lived and worked over four decades, and part of McCain's five-day, cross-country funeral procession. He died on August 25 at age 81. "His death seems to have reminded the American people that these values are what makes us a great nation, not the tribal partisanship and personal attack politics that have recently characterized our life, " said former Sen. Joe Lieberman of Connecticut, a longtime friend and fellow global traveler who McCain once considered as his vice presidential running mate. "This week's celebration of the life and values and patriotism of this hero, I think have taken our country above all that," he said.
"In a way, it's the last great gift that John McCain gave America." Trump, meanwhile, left the White House in the presidential motorcade shortly after 10:30 a.m., as the service was underway, headed to his Virginia golf course. Two of his top aides, White House chief of staff John Kelly and Defense Secretary James Mattis, flanked Cindy McCain as she placed the wreath at the memorial and joine the service. Trump's daughter Ivanka Trump and son-in-law Jared Kushner are attended.
McCain was a decorated veteran who was held for more than five years as a prisoner of war in Vietnam. He refused early release. Trump obtained deferments for his college education and a foot ailment.
McCain had long urged the Senate and the polarized nation to recognize the humanity even in bitter political opponents. McCain's request for speeches by the former presidents, to some, represents that ideal.
Article Type:
Report
Sections:
World
Agencies:
PTI
Tags:
John McCain
Cindy McCain
Meghan McCain
Donald Trump
Ivanka Trump
Barack Obama
Michelle Obama
Washington
James Mattis
Joe Lieberman
Hillary Clinton
Connecticut
White House
Sun, 2 Sep 2018-06:31pm
Date updated:
Sunday, 2 September 2018 - 6:31pm
Article Images:
Reuters
Short URL:
dnai.in/fDeM
Embargo:
Syndicate:
Hide lead image:
Page views:
1
Short Title:
When Obama took dig at Trump while remembering McCain
From Print Edition:
Highlights: Reported by DNA 6 hours ago.
↧
Congress manifesto panel convenes today
The newly-constituted 19-member Manifesto Committee framed by the Congress for 2019 Lok Sabha elections will have its maiden meeting on Monday. The party, under the leadership of Rahul Gandhi, promises a formidable alternative to BJP by putting economy, banking, social sectors and politik on track.
The committee comprises veterans like former union ministers P Chidambaram, Jairam Ramesh, Salman Khurshid and Kumari Shelja, former member of the Planning Commission Bhalchandra Mungekar and telecom inventor Sam Pitroda.
A veteran Congress leader, also on the committee, told DNA, "The party will focus on revitalization and revival of economy by giving a push to agriculture, industry, micro, small and medium enterprises and job creation, restoration of fiscal prudence, strategy to fight crony capitalism and resultant rampant corruption, creation of sense of security among all weaker sections including Dalit, tribal and minorities and protection of sanctity of democratic institutions.''
He informed that the party will highlight how the demonetization turned out to be an economic disaster and expose how Goods & Services Tax has become a bad word among business persons and common citizens. ''The party will recall economy grew at a faster rate during UPA rule and those days will be brought back by laying emphasis on inclusive growth,'' he said.
"Congress will spell out its strategy for a single slab GST for India. Rahul Gandhi, who has dubbed GST as Gabbar Singh Tax, has indicated the Congress will improve the implementation of the new indirect tax,'' the party leader said.
Further, in a bid to reassure party's support especially in the volatile economic situation, Congress party will promise the industry to address their concerns and bring transparency for greater ease of doing business.
The Congress also plans to dwell at length the politics of hate, division and violence that are trampling the Constitution and assure party's roadmap to restore social fabric and prominence of democratic institutions.
-*AMONG THE OBJECTIVES*-
· In a bid to reassure party’s support especially in the volatile economic situation, Congress party will promise the industry to address their concerns and bring transparency for greater ease of doing business
· Congress also plans to dwell at length the politics of hate, division and violence that are trampling the Constitution and assure party’s roadmap to restore social fabric and prominence of democratic institutions
Article Type:
Report
Sections:
India
Authors:
Sanjay Jog
Agencies:
DNA
Tags:
Congress
Bhalchandra Mungekar
Rahul Gandhi
bharatiya janata party
Jairam Ramesh
Lok Sabha
Salman Khurshid
Sam Pitroda
Dalit
2019 Lok Sabha elections
P Chidambaram
Mon, 3 Sep 2018-06:05am
Date updated:
Monday, 3 September 2018 - 6:05am
Article Images:
Rahul Gandhi
Short URL:
dnai.in/fDj6
Embargo:
Syndicate:
Hide lead image:
Page views:
1
From Print Edition:
Highlights: Reported by DNA 18 hours ago.
The committee comprises veterans like former union ministers P Chidambaram, Jairam Ramesh, Salman Khurshid and Kumari Shelja, former member of the Planning Commission Bhalchandra Mungekar and telecom inventor Sam Pitroda.
A veteran Congress leader, also on the committee, told DNA, "The party will focus on revitalization and revival of economy by giving a push to agriculture, industry, micro, small and medium enterprises and job creation, restoration of fiscal prudence, strategy to fight crony capitalism and resultant rampant corruption, creation of sense of security among all weaker sections including Dalit, tribal and minorities and protection of sanctity of democratic institutions.''
He informed that the party will highlight how the demonetization turned out to be an economic disaster and expose how Goods & Services Tax has become a bad word among business persons and common citizens. ''The party will recall economy grew at a faster rate during UPA rule and those days will be brought back by laying emphasis on inclusive growth,'' he said.
"Congress will spell out its strategy for a single slab GST for India. Rahul Gandhi, who has dubbed GST as Gabbar Singh Tax, has indicated the Congress will improve the implementation of the new indirect tax,'' the party leader said.
Further, in a bid to reassure party's support especially in the volatile economic situation, Congress party will promise the industry to address their concerns and bring transparency for greater ease of doing business.
The Congress also plans to dwell at length the politics of hate, division and violence that are trampling the Constitution and assure party's roadmap to restore social fabric and prominence of democratic institutions.
-*AMONG THE OBJECTIVES*-
· In a bid to reassure party’s support especially in the volatile economic situation, Congress party will promise the industry to address their concerns and bring transparency for greater ease of doing business
· Congress also plans to dwell at length the politics of hate, division and violence that are trampling the Constitution and assure party’s roadmap to restore social fabric and prominence of democratic institutions
Article Type:
Report
Sections:
India
Authors:
Sanjay Jog
Agencies:
DNA
Tags:
Congress
Bhalchandra Mungekar
Rahul Gandhi
bharatiya janata party
Jairam Ramesh
Lok Sabha
Salman Khurshid
Sam Pitroda
Dalit
2019 Lok Sabha elections
P Chidambaram
Mon, 3 Sep 2018-06:05am
Date updated:
Monday, 3 September 2018 - 6:05am
Article Images:
Rahul Gandhi
Short URL:
dnai.in/fDj6
Embargo:
Syndicate:
Hide lead image:
Page views:
1
From Print Edition:
Highlights: Reported by DNA 18 hours ago.
↧
Phoenix Veterans Affairs Center flooded with flowers after Sen. John McCain's death
The flowers were donated in honor of Sen. John McCain, per instructions left on his official website after his death.
Reported by azcentral.com 17 hours ago.
Reported by azcentral.com 17 hours ago.
↧
↧
Correction of a release from 31.08.2018, 07:56 CET/CEST - Biofrontera AG: Biofrontera reports significant revenue growth for the first 6 months of 2018
DGAP-News: Biofrontera AG / Key word(s): Half Year Results
03.09.2018 / 09:16
The issuer is solely responsible for the content of this announcement.
--------------------
*Biofrontera reports significant revenue growth for the first 6 months of 2018*
*Leverkusen, Germany, August 31, 2018* - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2018 and provided an update on recent operational and clinical developments.
- Total revenue increased 79% to approximately EUR 9.0 million for the first six months of 2018, compared to approximately EUR 5.0 million in the same period 2017.
- Product revenue increased 109% to approximately EUR 8.8 million for the first six months of 2018, compared to approximately EUR 4.2 million in the same period 2017.
- Net loss was approximately EUR 7.7 million or 0.18 per share in the first half of 2018, compared to approximately EUR 8.7 million or 0.23 per share, in the same period 2017.
- Grant of U.S. product-specific J-Code and revised CPT codes for more favorable reimbursement for photodynamic therapy (PDT) -prescribing physicians in January 2018.
- Successfully completed capital increase and dual listing on the U.S. NASDAQ Stock Market in February 2018.
- European Commission approved use of Ameluz^(R) in combination with daylight PDT in March 2018.
"Throughout the first half of 2018, we continued to make significant commercial and clinical advancements to optimize our product positioning and market potential of Ameluz^(R). In accordance with our strategy, we extended the approvals of Ameluz^(R) to include further uses and expanded our product sales," says Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "We successfully doubled our revenue from product sales in the first six months of 2018 compared to the first 6 months last year, primarily driven by sales in the U.S. as our sales force leverages improved reimbursement and coding clarity. In the EU, the label extensions of Ameluz^(R) for daylight photodynamic therapy and the the treatment for basal cell carcinoma (BCC) have begun to have a positive impact on our sales. Furthermore, the initiation of a U.S. Phase III trial for the treatment of BCC this September and results of our EU Phase III trial for the treatment of actinic keratoses on the extremities, trunk and neck expected in 2019, both represent future growth opportunities. We remain committed to the successful execution of our strategy for Ameluz^(R) as we position ourselves as a global leader in photodynamic therapy and drive long-term shareholder value," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
*First Half 2018 Financial Highlights:*
Thousands of EUR, except where noted *6M 2018* *6M 2017* *Change in %*
Revenue 8,969.2 5,006.4 79%
from product sales 8,837.9 4,221.5 109%
from development projects 91.3 784.9 (88%)
other 40.0 0.0 n/a
Research and development costs (2,187.7) (2,185.4) 0%
Sales costs (8,310.9) (8,275.3) 0%
General administrative costs (4,078.9) (1,695.5) (141%)
Net loss (7,684.9) (8,736.6) 12%
Earnings per share (in EUR) (0.18) (0.23) 28%
Biofrontera generated total revenue of approximately EUR 9.0 million in the first six months of 2018, representing 79% year-over-year growth. In the U.S., revenues increased 170% during the first half of 2018 to EUR 6.4 million, compared to the same period 2017. Sales in Germany improved slightly to EUR 1.2 million, representing a 7% increase compared to the previous year. Revenue in the remainder of Europe amounted to EUR 1.2 million, an increase of 65% compared to the same period last year.
Gross profit increased 67% to EUR 7.3 million in the first half of 2018 from EUR 4.4 million in the same period 2017. Gross margin decreased slightly to 81% in the first six months of 2018, compared to 87% for the same period in the previous year. One-time costs for the introduction of larger production batch sizes negatively affected gross margins.
The consolidated net loss for the first half of 2018 was EUR -7.7 million, or EUR -0.18 per share, compared to the net loss of EUR -8.7 million, or EUR -0.23 in the same period last year.
Cash and cash equivalents were EUR 26.3 million as of June 30, 2018, compared to EUR 11.1 million as of December 31, 2017.
Management reaffirms the current guidance, including revenues of EUR 16 to EUR 20 million for the full year 2018 and continues to expect a significant increase in revenue for the second half of 2018.
U.S. Commercial and Operational Update
Biofrontera continued to generate strong sales in the U.S., increasing 170% year-over-year to EUR 6.4 million for the first half of 2018. The Company's 53 U.S. employees, including 32 sales representatives and 5 regional managers, continue to ramp up sales as dermatologists become more familiar with Ameluz^(R) and leverage the Company's unique product-specific J-code (J7345) and revised CPT codes that significantly improved physician reimbursement.
In August 2018, Biofrontera was awarded a 5-year contract with the U.S. Department of Veterans Affairs (VA) for the sale of Ameluz^(R) in combination with the medical device BF-RhodoLED^(R). This contract allows Biofrontera to offer Ameluz^(R) to all VA as well as U.S. Department of Defense medical facilities. It further validates the efficacy of Ameluz^(R) and allows more patients to receive effective treatment.
EU Commercial Update
Biofrontera reported a 31% increase in revenues in all its European markets in the first half of 2018 as compared to the same period in 2017. With the initiation of sales of Ameluz^(R) for BCC and the European Commissions' approval for treatment with daylight PDT for actinic keratosis, Ameluz^(R) has become more competitive against existing PDT drugs, as well as patient-applied topical treatments. The Company further strengthens its market position with the launch of a dedicated UK sales team. In addition, Ameluz^(R) now qualifies for full reimbursement by public healthcare funds in Germany.
Recently, Biofrontera announced that it had completed patient recruitment for its Phase III trial of Ameluz^(R) and BF-RhodoLED^(R) for the treatment of actinic keratoses on the extremities, trunk and neck. The multi-center, randomized, double-blind, intra-individual study includes 50 patients at six study sites in Germany. Results of the trial are expected in the first quarter of 2019 with applications for marketing authorization extensions to be submitted to the European Medicines Agency and the FDA by the third quarter of 2019.
In February 2018, the Scottish Medicines Consortium recommended the prescription of Ameluz^(R) for the treatment of superficial or nodular basal cell carcinoma within the National Health Service.
Operational Update
In July 2018, Biofrontera announced the completion of phase 1 of its collaboration with Maruho Co., Ltd. Both companies are currently considering a continuation of the collaboration under a new agreement. However, no decision has yet been made concerning the details and timing of such a new agreement.
In February 2018, Biofrontera successfully completed its initial public offering in the U.S. of American Depositary Shares and concurrent preemptive rights offering of its ordinary shares to its existing holders of ordinary shares. The Company received aggregate net proceeds from its offerings of approximately EUR 21.6 million.
Conference Call
Conference calls for shareholders and interested investors will be held on August 31, 2018 at the following times:
In German, at 10:00 am CEST (4:00 am EDT)
Dial-in number Germany: +49 (0)69 2222 25204
Conference code: 3448423
In English, at 2:30 pm CEST (8:30 am EDT)
Dial-in number USA: +1 929 477 0402
Dial-in number UK: +44 (0)330 336 9411
Conference code: 5675352
Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.
The Company's half-year report including financial statements is available at
www.biofrontera.com/en/investors/financial-reports.
*-End-*
*For enquiries, please contact:
Biofrontera AG *
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
ir@biofrontera.com
*IR UK: Seton Services *
Toni Vallen
+44 (0) 207 224 8468
*IR and PR US: The Ruth Group*
IR: Tram Bui
PR: Kirsten Thomas
+1 646-536-7035
+1 508-280-6592
*About Biofrontera:*
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.
*Forward Looking Statements:*
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate,""believe,""forecast,""estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
--------------------
03.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service Reported by EQS Group 12 hours ago.
03.09.2018 / 09:16
The issuer is solely responsible for the content of this announcement.
--------------------
*Biofrontera reports significant revenue growth for the first 6 months of 2018*
*Leverkusen, Germany, August 31, 2018* - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2018 and provided an update on recent operational and clinical developments.
- Total revenue increased 79% to approximately EUR 9.0 million for the first six months of 2018, compared to approximately EUR 5.0 million in the same period 2017.
- Product revenue increased 109% to approximately EUR 8.8 million for the first six months of 2018, compared to approximately EUR 4.2 million in the same period 2017.
- Net loss was approximately EUR 7.7 million or 0.18 per share in the first half of 2018, compared to approximately EUR 8.7 million or 0.23 per share, in the same period 2017.
- Grant of U.S. product-specific J-Code and revised CPT codes for more favorable reimbursement for photodynamic therapy (PDT) -prescribing physicians in January 2018.
- Successfully completed capital increase and dual listing on the U.S. NASDAQ Stock Market in February 2018.
- European Commission approved use of Ameluz^(R) in combination with daylight PDT in March 2018.
"Throughout the first half of 2018, we continued to make significant commercial and clinical advancements to optimize our product positioning and market potential of Ameluz^(R). In accordance with our strategy, we extended the approvals of Ameluz^(R) to include further uses and expanded our product sales," says Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "We successfully doubled our revenue from product sales in the first six months of 2018 compared to the first 6 months last year, primarily driven by sales in the U.S. as our sales force leverages improved reimbursement and coding clarity. In the EU, the label extensions of Ameluz^(R) for daylight photodynamic therapy and the the treatment for basal cell carcinoma (BCC) have begun to have a positive impact on our sales. Furthermore, the initiation of a U.S. Phase III trial for the treatment of BCC this September and results of our EU Phase III trial for the treatment of actinic keratoses on the extremities, trunk and neck expected in 2019, both represent future growth opportunities. We remain committed to the successful execution of our strategy for Ameluz^(R) as we position ourselves as a global leader in photodynamic therapy and drive long-term shareholder value," commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
*First Half 2018 Financial Highlights:*
Thousands of EUR, except where noted *6M 2018* *6M 2017* *Change in %*
Revenue 8,969.2 5,006.4 79%
from product sales 8,837.9 4,221.5 109%
from development projects 91.3 784.9 (88%)
other 40.0 0.0 n/a
Research and development costs (2,187.7) (2,185.4) 0%
Sales costs (8,310.9) (8,275.3) 0%
General administrative costs (4,078.9) (1,695.5) (141%)
Net loss (7,684.9) (8,736.6) 12%
Earnings per share (in EUR) (0.18) (0.23) 28%
Biofrontera generated total revenue of approximately EUR 9.0 million in the first six months of 2018, representing 79% year-over-year growth. In the U.S., revenues increased 170% during the first half of 2018 to EUR 6.4 million, compared to the same period 2017. Sales in Germany improved slightly to EUR 1.2 million, representing a 7% increase compared to the previous year. Revenue in the remainder of Europe amounted to EUR 1.2 million, an increase of 65% compared to the same period last year.
Gross profit increased 67% to EUR 7.3 million in the first half of 2018 from EUR 4.4 million in the same period 2017. Gross margin decreased slightly to 81% in the first six months of 2018, compared to 87% for the same period in the previous year. One-time costs for the introduction of larger production batch sizes negatively affected gross margins.
The consolidated net loss for the first half of 2018 was EUR -7.7 million, or EUR -0.18 per share, compared to the net loss of EUR -8.7 million, or EUR -0.23 in the same period last year.
Cash and cash equivalents were EUR 26.3 million as of June 30, 2018, compared to EUR 11.1 million as of December 31, 2017.
Management reaffirms the current guidance, including revenues of EUR 16 to EUR 20 million for the full year 2018 and continues to expect a significant increase in revenue for the second half of 2018.
U.S. Commercial and Operational Update
Biofrontera continued to generate strong sales in the U.S., increasing 170% year-over-year to EUR 6.4 million for the first half of 2018. The Company's 53 U.S. employees, including 32 sales representatives and 5 regional managers, continue to ramp up sales as dermatologists become more familiar with Ameluz^(R) and leverage the Company's unique product-specific J-code (J7345) and revised CPT codes that significantly improved physician reimbursement.
In August 2018, Biofrontera was awarded a 5-year contract with the U.S. Department of Veterans Affairs (VA) for the sale of Ameluz^(R) in combination with the medical device BF-RhodoLED^(R). This contract allows Biofrontera to offer Ameluz^(R) to all VA as well as U.S. Department of Defense medical facilities. It further validates the efficacy of Ameluz^(R) and allows more patients to receive effective treatment.
EU Commercial Update
Biofrontera reported a 31% increase in revenues in all its European markets in the first half of 2018 as compared to the same period in 2017. With the initiation of sales of Ameluz^(R) for BCC and the European Commissions' approval for treatment with daylight PDT for actinic keratosis, Ameluz^(R) has become more competitive against existing PDT drugs, as well as patient-applied topical treatments. The Company further strengthens its market position with the launch of a dedicated UK sales team. In addition, Ameluz^(R) now qualifies for full reimbursement by public healthcare funds in Germany.
Recently, Biofrontera announced that it had completed patient recruitment for its Phase III trial of Ameluz^(R) and BF-RhodoLED^(R) for the treatment of actinic keratoses on the extremities, trunk and neck. The multi-center, randomized, double-blind, intra-individual study includes 50 patients at six study sites in Germany. Results of the trial are expected in the first quarter of 2019 with applications for marketing authorization extensions to be submitted to the European Medicines Agency and the FDA by the third quarter of 2019.
In February 2018, the Scottish Medicines Consortium recommended the prescription of Ameluz^(R) for the treatment of superficial or nodular basal cell carcinoma within the National Health Service.
Operational Update
In July 2018, Biofrontera announced the completion of phase 1 of its collaboration with Maruho Co., Ltd. Both companies are currently considering a continuation of the collaboration under a new agreement. However, no decision has yet been made concerning the details and timing of such a new agreement.
In February 2018, Biofrontera successfully completed its initial public offering in the U.S. of American Depositary Shares and concurrent preemptive rights offering of its ordinary shares to its existing holders of ordinary shares. The Company received aggregate net proceeds from its offerings of approximately EUR 21.6 million.
Conference Call
Conference calls for shareholders and interested investors will be held on August 31, 2018 at the following times:
In German, at 10:00 am CEST (4:00 am EDT)
Dial-in number Germany: +49 (0)69 2222 25204
Conference code: 3448423
In English, at 2:30 pm CEST (8:30 am EDT)
Dial-in number USA: +1 929 477 0402
Dial-in number UK: +44 (0)330 336 9411
Conference code: 5675352
Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.
The Company's half-year report including financial statements is available at
www.biofrontera.com/en/investors/financial-reports.
*-End-*
*For enquiries, please contact:
Biofrontera AG *
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
ir@biofrontera.com
*IR UK: Seton Services *
Toni Vallen
+44 (0) 207 224 8468
*IR and PR US: The Ruth Group*
IR: Tram Bui
PR: Kirsten Thomas
+1 646-536-7035
+1 508-280-6592
*About Biofrontera:*
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.
*Forward Looking Statements:*
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate,""believe,""forecast,""estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
--------------------
03.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service Reported by EQS Group 12 hours ago.
↧
Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018
Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2018 and provided an update on recent operational and clinical developments.
· Total revenue increased 79% to approximately EUR 9.0 million for the first six months of 2018, compared to approximately EUR 5.0 million in the same period 2017.
· Product revenue increased 109% to approximately EUR 8.8 million for the first six months of 2018, compared to approximately EUR 4.2 million in the same period 2017.
· Net loss was approximately EUR 7.7 million or 0.18 per share in the first half of 2018, compared to approximately EUR 8.7 million or 0.23 per share, in the same period 2017.
· Grant of U.S. product-specific J-Code and revised CPT codes for more favorable reimbursement for photodynamic therapy (PDT) -prescribing physicians in January 2018.
· Successfully completed capital increase and dual listing on the U.S. NASDAQ Stock Market in February 2018.
· European Commission approved use of Ameluz^® in combination with daylight PDT in March 2018.
“Throughout the first half of 2018, we continued to make significant commercial and clinical advancements to optimize our product positioning and market potential of Ameluz^®. In accordance with our strategy, we extended the approvals of Ameluz^® to include further uses and expanded our product sales,” says Prof. Dr. Hermann Lübbert, CEO of Biofrontera. “We successfully doubled our revenue from product sales in the first six months of 2018 compared to the first 6 months last year, primarily driven by sales in the U.S. as our sales force leverages improved reimbursement and coding clarity. In the EU, the label extensions of Ameluz^® for daylight photodynamic therapy and the the treatment for basal cell carcinoma (BCC) have begun to have a positive impact on our sales. Furthermore, the initiation of a U.S. Phase III trial for the treatment of BCC this September and results of our EU Phase III trial for the treatment of actinic keratoses on the extremities, trunk and neck expected in 2019, both represent future growth opportunities. We remain committed to the successful execution of our strategy for Ameluz^® as we position ourselves as a global leader in photodynamic therapy and drive long-term shareholder value,” commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
*First Half 2018 Financial Highlights:*
Thousands of EUR, except where noted * * *6M 2018* * * * * *6M 2017* * * * * *Change in %* * *
Revenue 8,969.2 5,006.4 79 %
from product sales 8,837.9 4,221.5 109 %
from development projects 91.3 784.9 (88 %)
other 40.0 0.0 n/a
Research and development costs (2,187.7 ) (2,185.4 ) %
Sales costs (8,310.9 ) (8,275.3 ) %
General administrative costs (4,078.9 ) (1,695.5 ) (141 %)
Net loss (7,684.9 ) (8,736.6 ) 12 %
Earnings per share (in EUR) (0.18 ) (0.23 ) 28 %
Biofrontera generated total revenue of approximately EUR 9.0 million in the first six months of 2018, representing 79% year-over-year growth. In the U.S., revenues increased 170% during the first half of 2018 to EUR 6.4 million, compared to the same period 2017. Sales in Germany improved slightly to EUR 1.2 million, representing a 7% increase compared to the previous year. Revenue in the remainder of Europe amounted to EUR 1.2 million, an increase of 65% compared to the same period last year.
Gross profit increased 67% to EUR 7.3 million in the first half of 2018 from EUR 4.4 million in the same period 2017. Gross margin decreased slightly to 81% in the first six months of 2018, compared to 87% for the same period in the previous year. One-time costs for the introduction of larger production batch sizes negatively affected gross margins.
The consolidated net loss for the first half of 2018 was EUR -7.7 million, or EUR -0.18 per share, compared to the net loss of EUR -8.7 million, or EUR -0.23 in the same period last year.
Cash and cash equivalents were EUR 26.3 million as of June 30, 2018, compared to EUR 11.1 million as of December 31, 2017.
Management reaffirms the current guidance, including revenues of EUR 16 to EUR 20 million for the full year 2018 and continues to expect a significant increase in revenue for the second half of 2018.
U.S. Commercial and Operational Update
Biofrontera continued to generate strong sales in the U.S., increasing 170% year-over-year to EUR 6.4 million for the first half of 2018. The Company’s 53 U.S. employees, including 32 sales representatives and 5 regional managers, continue to ramp up sales as dermatologists become more familiar with Ameluz^® and leverage the Company’s unique product-specific J-code (J7345) and revised CPT codes that significantly improved physician reimbursement.
In August 2018, Biofrontera was awarded a 5-year contract with the U.S. Department of Veterans Affairs (VA) for the sale of Ameluz^® in combination with the medical device BF-RhodoLED^®. This contract allows Biofrontera to offer Ameluz^® to all VA as well as U.S. Department of Defense medical facilities. It further validates the efficacy of Ameluz^® and allows more patients to receive effective treatment.
EU Commercial Update
Biofrontera reported a 31% increase in revenues in all our European markets in the first half of 2018 as compared to the same period in 2017. With the initiation of sales of Ameluz^® for BCC and the European Commissions’ approval for treatment with daylight PDT for actinic keratosis, Ameluz^® has become more competitive against existing PDT drugs, as well as patient-applied topical treatments. The Company further strengthens its market position with the launch of a dedicated UK sales team. In addition, Ameluz^® now qualifies for full reimbursement by public healthcare funds in Germany.
Recently, Biofrontera announced that it had completed patient recruitment for its Phase III trial of Ameluz^® and BF-RhodoLED^® for the treatment of actinic keratoses on the extremities, trunk and neck. The multi-center, randomized, double-blind, intra-individual study includes 50 patients at six study sites in Germany. Results of the trial are expected in the first quarter of 2019 with applications for marketing authorization extensions to be submitted to the European Medicines Agency and the FDA by the third quarter of 2019.
In February 2018, the Scottish Medicines Consortium recommended the prescription of Ameluz^® for the treatment of superficial or nodular basal cell carcinoma within the National Health Service.
Operational Update
In July 2018, Biofrontera announced the completion of phase 1 of its collaboration with Maruho Co., Ltd. Both companies are currently considering a continuation of the collaboration under a new agreement. However, no decision has yet been made concerning the details and timing of such a new agreement.
In February 2018, Biofrontera successfully completed its initial public offering in the U.S. of American Depositary Shares and concurrent preemptive rights offering of its ordinary shares to its existing holders of ordinary shares. The Company received aggregate net proceeds from its offerings of approximately EUR 21.6 million.
Conference Call
Conference calls for shareholders and interested investors will be held on August 31, 2018 at the following times:
In German, at 10:00 am CEST (4:00 am EDT)
Dial-in number Germany: +49 (0)69 2222 25204
Conference code: 3448423
In English, at 2:30 pm CEST (8:30 am EDT)
Dial-in number USA: +1 929 477 0402
Dial-in number UK: +44 (0)330 336 9411
Conference code: 5675352
Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.
The Company’s half-year report including financial statements is available at
www.biofrontera.com/en/investors/financial-reports.
*-End-*
*For enquiries, please contact: *
*Biofrontera AG *
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
ir@biofrontera.com
*IR UK: Seton Services *
Toni Vallen
+44 (0) 207 224 8468
*IR and PR US: The Ruth Group*
IR: Tram Bui
PR: Kirsten Thomas
+1 646-536-7035
+1 508-280-6592
*About Biofrontera:*
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.
*Forward Looking Statements:*
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate,""believe,""forecast,""estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement. Reported by GlobeNewswire 9 hours ago.
· Total revenue increased 79% to approximately EUR 9.0 million for the first six months of 2018, compared to approximately EUR 5.0 million in the same period 2017.
· Product revenue increased 109% to approximately EUR 8.8 million for the first six months of 2018, compared to approximately EUR 4.2 million in the same period 2017.
· Net loss was approximately EUR 7.7 million or 0.18 per share in the first half of 2018, compared to approximately EUR 8.7 million or 0.23 per share, in the same period 2017.
· Grant of U.S. product-specific J-Code and revised CPT codes for more favorable reimbursement for photodynamic therapy (PDT) -prescribing physicians in January 2018.
· Successfully completed capital increase and dual listing on the U.S. NASDAQ Stock Market in February 2018.
· European Commission approved use of Ameluz^® in combination with daylight PDT in March 2018.
“Throughout the first half of 2018, we continued to make significant commercial and clinical advancements to optimize our product positioning and market potential of Ameluz^®. In accordance with our strategy, we extended the approvals of Ameluz^® to include further uses and expanded our product sales,” says Prof. Dr. Hermann Lübbert, CEO of Biofrontera. “We successfully doubled our revenue from product sales in the first six months of 2018 compared to the first 6 months last year, primarily driven by sales in the U.S. as our sales force leverages improved reimbursement and coding clarity. In the EU, the label extensions of Ameluz^® for daylight photodynamic therapy and the the treatment for basal cell carcinoma (BCC) have begun to have a positive impact on our sales. Furthermore, the initiation of a U.S. Phase III trial for the treatment of BCC this September and results of our EU Phase III trial for the treatment of actinic keratoses on the extremities, trunk and neck expected in 2019, both represent future growth opportunities. We remain committed to the successful execution of our strategy for Ameluz^® as we position ourselves as a global leader in photodynamic therapy and drive long-term shareholder value,” commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
*First Half 2018 Financial Highlights:*
Thousands of EUR, except where noted * * *6M 2018* * * * * *6M 2017* * * * * *Change in %* * *
Revenue 8,969.2 5,006.4 79 %
from product sales 8,837.9 4,221.5 109 %
from development projects 91.3 784.9 (88 %)
other 40.0 0.0 n/a
Research and development costs (2,187.7 ) (2,185.4 ) %
Sales costs (8,310.9 ) (8,275.3 ) %
General administrative costs (4,078.9 ) (1,695.5 ) (141 %)
Net loss (7,684.9 ) (8,736.6 ) 12 %
Earnings per share (in EUR) (0.18 ) (0.23 ) 28 %
Biofrontera generated total revenue of approximately EUR 9.0 million in the first six months of 2018, representing 79% year-over-year growth. In the U.S., revenues increased 170% during the first half of 2018 to EUR 6.4 million, compared to the same period 2017. Sales in Germany improved slightly to EUR 1.2 million, representing a 7% increase compared to the previous year. Revenue in the remainder of Europe amounted to EUR 1.2 million, an increase of 65% compared to the same period last year.
Gross profit increased 67% to EUR 7.3 million in the first half of 2018 from EUR 4.4 million in the same period 2017. Gross margin decreased slightly to 81% in the first six months of 2018, compared to 87% for the same period in the previous year. One-time costs for the introduction of larger production batch sizes negatively affected gross margins.
The consolidated net loss for the first half of 2018 was EUR -7.7 million, or EUR -0.18 per share, compared to the net loss of EUR -8.7 million, or EUR -0.23 in the same period last year.
Cash and cash equivalents were EUR 26.3 million as of June 30, 2018, compared to EUR 11.1 million as of December 31, 2017.
Management reaffirms the current guidance, including revenues of EUR 16 to EUR 20 million for the full year 2018 and continues to expect a significant increase in revenue for the second half of 2018.
U.S. Commercial and Operational Update
Biofrontera continued to generate strong sales in the U.S., increasing 170% year-over-year to EUR 6.4 million for the first half of 2018. The Company’s 53 U.S. employees, including 32 sales representatives and 5 regional managers, continue to ramp up sales as dermatologists become more familiar with Ameluz^® and leverage the Company’s unique product-specific J-code (J7345) and revised CPT codes that significantly improved physician reimbursement.
In August 2018, Biofrontera was awarded a 5-year contract with the U.S. Department of Veterans Affairs (VA) for the sale of Ameluz^® in combination with the medical device BF-RhodoLED^®. This contract allows Biofrontera to offer Ameluz^® to all VA as well as U.S. Department of Defense medical facilities. It further validates the efficacy of Ameluz^® and allows more patients to receive effective treatment.
EU Commercial Update
Biofrontera reported a 31% increase in revenues in all our European markets in the first half of 2018 as compared to the same period in 2017. With the initiation of sales of Ameluz^® for BCC and the European Commissions’ approval for treatment with daylight PDT for actinic keratosis, Ameluz^® has become more competitive against existing PDT drugs, as well as patient-applied topical treatments. The Company further strengthens its market position with the launch of a dedicated UK sales team. In addition, Ameluz^® now qualifies for full reimbursement by public healthcare funds in Germany.
Recently, Biofrontera announced that it had completed patient recruitment for its Phase III trial of Ameluz^® and BF-RhodoLED^® for the treatment of actinic keratoses on the extremities, trunk and neck. The multi-center, randomized, double-blind, intra-individual study includes 50 patients at six study sites in Germany. Results of the trial are expected in the first quarter of 2019 with applications for marketing authorization extensions to be submitted to the European Medicines Agency and the FDA by the third quarter of 2019.
In February 2018, the Scottish Medicines Consortium recommended the prescription of Ameluz^® for the treatment of superficial or nodular basal cell carcinoma within the National Health Service.
Operational Update
In July 2018, Biofrontera announced the completion of phase 1 of its collaboration with Maruho Co., Ltd. Both companies are currently considering a continuation of the collaboration under a new agreement. However, no decision has yet been made concerning the details and timing of such a new agreement.
In February 2018, Biofrontera successfully completed its initial public offering in the U.S. of American Depositary Shares and concurrent preemptive rights offering of its ordinary shares to its existing holders of ordinary shares. The Company received aggregate net proceeds from its offerings of approximately EUR 21.6 million.
Conference Call
Conference calls for shareholders and interested investors will be held on August 31, 2018 at the following times:
In German, at 10:00 am CEST (4:00 am EDT)
Dial-in number Germany: +49 (0)69 2222 25204
Conference code: 3448423
In English, at 2:30 pm CEST (8:30 am EDT)
Dial-in number USA: +1 929 477 0402
Dial-in number UK: +44 (0)330 336 9411
Conference code: 5675352
Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.
The Company’s half-year report including financial statements is available at
www.biofrontera.com/en/investors/financial-reports.
*-End-*
*For enquiries, please contact: *
*Biofrontera AG *
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
ir@biofrontera.com
*IR UK: Seton Services *
Toni Vallen
+44 (0) 207 224 8468
*IR and PR US: The Ruth Group*
IR: Tram Bui
PR: Kirsten Thomas
+1 646-536-7035
+1 508-280-6592
*About Biofrontera:*
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.
*Forward Looking Statements:*
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate,""believe,""forecast,""estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement. Reported by GlobeNewswire 9 hours ago.
↧
Petraeus: US has ‘sacred obligation’ to help burn-pit veterans
Army Gen. David Petraeus, who was instrumental in guiding U.S. troops during the Iraq War, says that America’s service members should be receiving assistance for the mounting medical issues that they fear have come as a result of being exposed to burn pits while stationed at military bases.
Reported by FOXNews.com 8 hours ago.
↧
Marijuana startups handling millions of dollars are forced to hide cash and use secure vaults because they’re shut out of the banking system
· *The US marijuana industry is booming in a number of states, but the federal government considers marijuana an illegal, Schedule I drug.*· *Because of that, most banks won't touch the industry. And they won't lend money either.*
· *That's forced marijuana startups to come up with creative solutions to raise money, finance growth, file taxes, and pay employees.*
--------------------
Twice a week, Emmett Reistroffer carefully watches his array of security cameras. When the coast is clear, an armed guard walks into his facility.
When the guard — a former law enforcement officer — enters, Reistroffer sits down with an accountant and the guard to count stacks of cash.
Riestroffer is the Director of Compliance at Silver State Wellness, a state-legal Nevada cannabis business.
The guard is a heavily armed cash courier, and this highly-choreographed meetup is the reality of doing business in Nevada's cannabis industry. Riestroffer is just trying to pay Silver State's vendors on time — and everything has to be in cash.
While marijuana is legal in a number of states, the federal government still considers it an illegal, Schedule I drug. Because of that, many marijuana startups — though fully compliant with state law — are shut out of the banking system.
Marijuana companies that deal with the plant directly, like cultivators, distributors, and dispensaries, are forced to come up with creative solutions to do business on an all-cash basis. That's where the armored guards come in.
"The process is highly secure," Riestroffer told Business Insider. "We plan the cash drops when the facility is relatively empty."
Riestroffer said the word "cash" never appears in any of his text messages or emails to the courier and vendors he needs to pay.
While Riestroffer wouldn't say exactly how much cash he handles on the twice-weekly drops, it's upwards of $100,000. He said other cannabis businesses he knows of are handling cash "into the millions."
"We try and minimize as much as possible who needs to know, and what the courier is coming to do at our facility," he said.
Beyond the obvious public safety and theft issues of piles of cash moving around Las Vegas in armored trucks, it's "a huge burden on my time," Riestroffer said, adding that he has to account for every single transaction purely in cash.
It's also a problem for paying vendors, many of whom don't want or won't accept cash payments, Riestroffer said.
*No banks and no loans = lots of problems*
The marijuana business is booming in the US. According to a report from the investment bank Cowen, legal marijuana is set to hit $75 billion in sales by 2030, putting it on par with soda consumption. Marijuana cultivators are now listed on the NASDAQ, have former politicians on their board, and are backed by heavyweight investors like Leon Cooperman.
But for many big institutions, the risks of banking and lending to the cannabis industry under the current federal mandate just aren't worth it, especially with all the extra paperwork and scrutiny it can generate.
"For cannabis businesses, this means that access to the basic financial products like checking and savings accounts can be elusive," John Hudak, a senior fellow at the Brookings Institution who studies issues pertaining to marijuana legalization, told Business Insider.
Tyler Beuerlein, a VP at Hypur, an Arizona-based fintech startup that acts as a middleman between banks and cannabis companies, told Business Insider that he believes there are "less than 30" banks willing to do business with the booming cannabis industry in the US.
That means the costs of doing business and remaining compliant with the byzantine patchwork of state and federal laws guiding the cannabis sector are much higher than in any other industry.
There's also a higher risk of fraud in cash-only businesses, according to Hudak. As a result, cannabis businesses have had to resort to creative accounting in order to do the things any normal business would, like paying employees and filing taxes.
"The way it works in Nevada, the employees are actually contractors of a parent organization," Riestroffer said. "The contractors work for the facility, but they're really employed by another entity."
That system allows Silver State to pay employees regularly through direct deposit, which Riestroffer said is "really lucky." Other companies are forced to pay employees in cash, which creates its own obvious headaches for state regulators.
Because of a section of the federal tax code that doesn't allow cannabis companies to deduct business expenses, these startups end up paying an effective tax rate "3.5 times higher than their neighboring businesses," Keegan Peterson, the CEO of Wurk, a Colorado-based payroll and compliance firm, told Business Insider.
*California is a little further along than Nevada *
While California is a little further along in terms of cannabis banking access than Nevada (and most other states that have legalized marijuana), similar issues remain.
John Cochran, the CEO of Loudpack, a marijuana distribution and cultivation company based in the Golden State, said there are a number of credit unions willing to bank his business.
But in the "old days," which in the marijuana industry means two or three years ago, "I'm sure there were lots of people that paid their employees in cash in some form," he said.
While credit unions will open basic checking accounts for California cannabis businesses, institutional banks still won't lend to the cannabis industry, which hurts entrepreneurs across the board.
It's a question of "whether the juice is worth the squeeze" for the big banks, Cochran said. Banks don't want to invite the scrutiny that lending to a federally illegal industry would bring.
*Cannabis industry entrepreneurs have one option to finance growth *
Borrowing money is almost impossible in the cannabis industry. Just as with employees' payments, cannabis operators are forced to come up with creative solutions to finance growth.
To finance a new business, firms usually have two basic options: they can use debt, by taking a loan and negotiating an interest rate with a bank, or they can trade equity by hitting up a venture firm — a process known as dilution.
Instead of going to banks and underwriting a loan backed by whatever assets a company has, most cannabis companies raise money from wealthy individuals who are willing to take risks that banks won't.
But in order to protect their capital in what amounts to a risky investment, these wealthy individuals — much like angel investors or seed-stage venture capital firms — want something for their money. That something usually amounts to a huge equity stake, Kris Krane, the president of 4Front Ventures, a firm that invests and manages a network of marijuana dispensaries across the US told Business Insider.
For example, 4Front was recently granted a license to open a dispensary in Western Massachusetts.
But 4Front can't get a loan to build in the state, so it's forced to hit up private investors. "We basically have to take dilution and sell pieces of the company we otherwise wouldn't have," Krane said.
For a firm like 4Front, which seeks to purchase many licenses in states with legal marijuana to build a network of dispensaries, each new license means more equity dilution, according to Krane.
"We all own less of our company then we would have owned if we had access to traditional banking and lending," Krane said.
For well-connected and well-capitalized companies like 4Front — which is composed of Wall Street veterans — this is a surmountable problem.
*A lack of institutional lending hurts small business owners the most*
Where it really hurts, according to Krane, is with the "mom-and-pops" and small businesses.
In states like Massachusetts, which allocate a certain percentage of their dispensary licenses to "equity applicants," who are below certain income thresholds or who may have a past drug conviction, the lack of access to lending puts these license holders at a disadvantage.
"They're going to wind up owning substantially less than their well-capitalized counterparts," Krane said. Like 4Front, these applicants will be forced to rely on private investors to finance their dispensary, instead of banks.
These applicants, who may not have relevant management experience and who may be less connected to networks of high-net-worth investors, can get taken advantage of by private investors.
It puts equity applicants and small business owners in a position where "it's almost impossible for them to keep majority control of their company," Krane said, "because they don't have that access to institutional lending where they could just get a loan and do this on their own and keep a larger chunk of that business."
Hudak agrees. "For those without access to liquid capital, they are forced to recruit more investors than a traditional business would need," which means they'll end up losing more control of their operation.
*Institutions 'want to be at the table'*
Right now, the only way for cannabis companies to get institutional money is to tap into public markets in Canada, where marijuana is set to be legalized federally in October. But US institutions want the "upside" of what's going on in Canada, Cochran said — especially as bigger public cannabis companies in Canada see their valuations soar as they go on acquisition sprees.
"There's a lot of institutional money in the state that wants to be at the table," Cochran, the CEO of Loudpack said.
Senators Cory Gardner and Elizabeth Warren have introduced the bipartisan STATES Act, which would essentially provide an exception from the Controlled Substances Act for states that choose to legalize marijuana, allowing banks to lend to the industry.
President Donald Trump indicated that he'd support the legislation if it crossed its desk.
"The STATES ACT could theoretically solve the banking issue," Krane, of 4Front said. "But it won't solve all of our problems."
Until then, the cannabis industry will have to remain adaptable — and creative.
*Read more of Business Insider's marijuana industry coverage:*
· The rising stars of marijuana's investment scene that everyone from Wall Street to Silicon Valley should know
· The highest-valued marijuana companies of 2017 reveal 2 key insights about the booming industry
· One of the hedge funders behind 'The Big Short' says betting on marijuana is the 'big long'
· A top cannabis private equity fund manager reveals how he picks companies to invest in
· Beer giants like Heineken and Constellation Brands are duking it out in the billion-dollar market for marijuana-infused drinks
*SEE ALSO: Hedge fund legend Leon Cooperman is investing in the marijuana industry — and it's another sign the sector is heating up*
Join the conversation about this story »
NOW WATCH: The world's most dangerous venomous animals are all in Australia Reported by Business Insider 4 hours ago.
↧
↧
A Journeyman’s Run to Become the Most Unlikely Packer
Since coming to the NFL undrafted out of a Division-III program, receiver Jake Kumerow has three times come up short trying to make a roster. In July, he was sitting behind three established veterans and three freshly drafted rookies. He played well enough to earn the respect of his Hall of Fame quarterback and become a fan favorite. On cut-down day, he was waiting for a call…
Reported by SI.com 2 hours ago.
↧
Your6™ Wins the First-Time Entrepreneur Category at the 2018 Greater Austin Business Awards
Your6™ won the 2018 Business Award for First-Time Entrepreneur. The award was presented by the Austin Chamber of Commerce on August 30, 2018.
AUSTIN, Texas (PRWEB) September 03, 2018
Your6™ won the 2018 Business Award for First-Time Entrepreneur. The award was presented by the Austin Chamber of Commerce on August 30, 2018. The ceremony recognizes businesses and organizations for achievements, community contributions and milestones. It is the largest business event in Central Texas, bringing together 1,000 business leaders, entrepreneurs, organizations, government officials and regionals chambers. When asked for comment, Doug Quitmeyer, founder & CEO of Your6™ said, "I am humbled and honored that Your6™ had been selected among such outstanding businesses and entrepreneurs in the greater Austin Area. I am grateful for all the hard work that everyone on the Your6™ team has done, and all of the support and assistance we have received from the Austin Community as we grow. Lastly, I have to say that I couldn't do what I need to without the support of my wife Angela, who basically holds everything else down so I can concentrate on Your6™'s mission of revolutionizing hiring and career transitions."
Veteran Staff Sgt. Doug Quitmeyer, was a member of the 75th Ranger Regiment, where he was both a sniper team leader and team leader. He executed multiple deployments in support of Operations Enduring Freedom and Iraqi Freedom. Doug left the 75th Ranger Regiment to become a liaison instructor with units in the US Navy. While there, he was responsible for developing, auditing and updating training curriculum, as well as training in tactics, techniques, and procedures in land warfare environment. Following his discharge, Quitmeyer became an instructor in firearms tactics for police officers and military units. Eventually, he presented his resume to a state workforce commission, which recommended positions as an exterminator or security guard based on his military skills, a verdict that left Quitmeyer disenchanted and disheartened with how veterans are perceived in the civilian workplace.
Your6™ was started to provide an outlet to change people’s awareness of their own capabilities and potential. Some of the job seeker services offered by Your6™ include individual assessments, resume services and coaching services. Your6™ also offers services for Employers to assess their entire applicant group accurately.
For more information about Your6™, please visit http://www.your6usa.com.
About Your6™
Your6™ is a business intelligence hiring firm focused on providing an array of innovative hiring and transition tools and services, including customized assessments, advanced data analytics, and leadership that helps veterans and organizations achieve the best possible employment opportunities. We operate as a conduit between transforming the language of military experience and individual potential, translating it into the civilian lexicon, and aligning candidates with the best opportunities, helping you make the most informed hiring decision for your company. Your6™ was built by former servicemen and women in partnership with civilians with deep corporate experience.
We’re here to modernize and revolutionize hiring and career transitions.
Release Issued by Audience Generation, LLC
Audience Generation is a forward-thinking agency at the forefront of the digital revolution and is a nationally and internationally recognized provider of integrated marketing, advertising, and technology services and solutions that offer a new way to find, generate, and engage live, online, social, and mobile audiences where they exist on demand.
Audience Generation is known for its creative strategy, actionable solutions and measurable approach to transforming the ways brands interact with their target audience, whether they exist in person, online, via social networks, or on their mobile devices.
Audience Generation has produced winning traditional, online, e-commerce, social and mobile campaigns including mobile application solutions for Fortune 500, small and medium businesses, not-for-profit organizations, national and international associations and societies, and venture-backed start-up companies across a variety of industry verticals around the world.
To learn how Audience Generation can find your ideal customer, reach them where they exist, build your brand, and grow your bottom line, please call us at 512-708-4678 or email us at mwayne@audiencegeneration.com or visit us at http://www.audiencegeneration.com. Reported by PRWeb 1 hour ago.
AUSTIN, Texas (PRWEB) September 03, 2018
Your6™ won the 2018 Business Award for First-Time Entrepreneur. The award was presented by the Austin Chamber of Commerce on August 30, 2018. The ceremony recognizes businesses and organizations for achievements, community contributions and milestones. It is the largest business event in Central Texas, bringing together 1,000 business leaders, entrepreneurs, organizations, government officials and regionals chambers. When asked for comment, Doug Quitmeyer, founder & CEO of Your6™ said, "I am humbled and honored that Your6™ had been selected among such outstanding businesses and entrepreneurs in the greater Austin Area. I am grateful for all the hard work that everyone on the Your6™ team has done, and all of the support and assistance we have received from the Austin Community as we grow. Lastly, I have to say that I couldn't do what I need to without the support of my wife Angela, who basically holds everything else down so I can concentrate on Your6™'s mission of revolutionizing hiring and career transitions."
Veteran Staff Sgt. Doug Quitmeyer, was a member of the 75th Ranger Regiment, where he was both a sniper team leader and team leader. He executed multiple deployments in support of Operations Enduring Freedom and Iraqi Freedom. Doug left the 75th Ranger Regiment to become a liaison instructor with units in the US Navy. While there, he was responsible for developing, auditing and updating training curriculum, as well as training in tactics, techniques, and procedures in land warfare environment. Following his discharge, Quitmeyer became an instructor in firearms tactics for police officers and military units. Eventually, he presented his resume to a state workforce commission, which recommended positions as an exterminator or security guard based on his military skills, a verdict that left Quitmeyer disenchanted and disheartened with how veterans are perceived in the civilian workplace.
Your6™ was started to provide an outlet to change people’s awareness of their own capabilities and potential. Some of the job seeker services offered by Your6™ include individual assessments, resume services and coaching services. Your6™ also offers services for Employers to assess their entire applicant group accurately.
For more information about Your6™, please visit http://www.your6usa.com.
About Your6™
Your6™ is a business intelligence hiring firm focused on providing an array of innovative hiring and transition tools and services, including customized assessments, advanced data analytics, and leadership that helps veterans and organizations achieve the best possible employment opportunities. We operate as a conduit between transforming the language of military experience and individual potential, translating it into the civilian lexicon, and aligning candidates with the best opportunities, helping you make the most informed hiring decision for your company. Your6™ was built by former servicemen and women in partnership with civilians with deep corporate experience.
We’re here to modernize and revolutionize hiring and career transitions.
Release Issued by Audience Generation, LLC
Audience Generation is a forward-thinking agency at the forefront of the digital revolution and is a nationally and internationally recognized provider of integrated marketing, advertising, and technology services and solutions that offer a new way to find, generate, and engage live, online, social, and mobile audiences where they exist on demand.
Audience Generation is known for its creative strategy, actionable solutions and measurable approach to transforming the ways brands interact with their target audience, whether they exist in person, online, via social networks, or on their mobile devices.
Audience Generation has produced winning traditional, online, e-commerce, social and mobile campaigns including mobile application solutions for Fortune 500, small and medium businesses, not-for-profit organizations, national and international associations and societies, and venture-backed start-up companies across a variety of industry verticals around the world.
To learn how Audience Generation can find your ideal customer, reach them where they exist, build your brand, and grow your bottom line, please call us at 512-708-4678 or email us at mwayne@audiencegeneration.com or visit us at http://www.audiencegeneration.com. Reported by PRWeb 1 hour ago.
↧
Montana Sen. Tester talks up Trump to defuse GOP challenge
BILLINGS, Mont. (AP) — U.S. Sen. Jon Tester is rolling out a new television ad promoting his collaboration with President Donald Trump as the Montana Democrat seeks to inoculate himself against conservative critics ahead of Trump’s upcoming visit to the state. The ad, scheduled to air Thursday, highlights veterans’ health care legislation from Tester that […]
Reported by Seattle Times 21 hours ago.
↧
Hometown heroes: OBJ honors 2018 Veterans of Influence
This year's award winners pointed to their military training and skills as the impetus behind their accomplishments in the business world.
Reported by bizjournals 22 hours ago.
↧
↧
Amazon's Jeff Bezos donates $10 million to PAC; Sanders introduces the BEZOS Act
Bezos and his wife MacKenzie have donated $10 million to the With Honor Fund, a super PAC that works to get military veterans elected to Congress. Also Sen. Bernie Sanders introduced a bill aimed at Amazon employees.
Reported by USATODAY.com 21 hours ago.
Reported by USATODAY.com 21 hours ago.
↧
Thomas Bjorn stands up for his Ryder Cup veterans
Ryder Cup captain Thomas Bjorn launched a passionate defence of his contentious wild card picks last night, insisting: 'it's more important to have the best team rather than the best players.'
Reported by MailOnline 22 hours ago.
↧
Jeff Bezos Gives $10 Million to Help Elect Veterans to Congress
Jeff Bezos, the richest man in the world, is throwing around some serious cash ... and it's politically motivated. The founder and CEO of Amazon, is donating $10,000,000 to help veterans get elected to Congress ... and that's not a typo, it's…
Reported by TMZ.com 18 hours ago.
↧
More Pages to Explore .....
